Why GW Pharmaceuticals Stock Rose 10% in January
After an underwhelming 2019, shares of GW Pharmaceuticals (NASDAQ: GWPH) perked up nicely in January, with the drugmaker's stock jumping 10% for the month, according to data from S&P Global Market Intelligence. The gain last month came in response to the company's preliminary fourth-quarter and full-year results released on Jan. 12.
The major headline is the rapidly growing sales of the company's cannabis-based epilepsy medicine Epidiolex. During its first full year of sales as a treatment for two rare but potentially deadly forms of childhood epilepsy, Epidiolex hauled in an astounding $296 million.
Image source: Getty Images.
Source Fool.com
